title: Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?
abstract: Champiat and colleagues suggest that a small subset of patients at their center treated with PD1/PDL1 inhibitors appear to exhibit hyperprogression of disease. This commentary goes over some limitations in their preliminary analysis, a possible mechanism to explain the phenomenon, and a means by which other investigators can attempt to validate and further characterize these results.Clin Cancer Res; 23(8); 1879-81. ©2017 AACRSee related article by Champiat et al., p. 1920.
authors.affiliation: Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. sharone@mail.nih.gov.
authors.forename: Elad
authors.initials: E
authors.lastname: Sharon
mesh_terms: D006801:Humans; D009369:Neoplasms